Abstract:
16 Noroviruses (NoVs) are a leading cause of gastroenteritis world-wide, yet host proven difficult to culture in vitro with significant advances made only in the past few 52 years [3, 4] . Because of the challenges in growing HNoV in cell culture and lack of an 53 animal model, murine norovirus (MNoV) has emerged as a system for understanding 54 norovirus biology. MNoV grows robustly in cell culture, is amenable to reverse genetics, 55 and is a natural pathogen of laboratory mice. MNoV is similar to HNoV in that both HeLa-CD300lf cell lines (BV2-dCas9-VP64 and HeLa-CD300lf-dCas9-VP64).
106
Before proceeding with a genome-wide screen, we developed a simple assay to 107 test transcriptional activation activity in BV2-dCas9-VP64 and HeLa-CD300lf-dCas9- Figure 1A ). This new system is advantageous 118 over the previous synergistic activation mediator (SAM) RNA polymerase gene expression (Table 2 ). These data demonstrate the ability to 166 discover expected candidate antiviral genes (e.g. those regulated by inflammatory 167 cytokines) and candidate genes involved in other pathways (e.g. embryogenesis).
169
Analysis and comparison of screen in BV2 and HeLa cells 170 We compared the results from the BV2 and HeLa-CD300lf CRISPRa screens.
171
The top hit in all virus and cell type combinations was TRIM7 ( Figure 2A and Tables S1- (Tables S1-S4) . When looking at the 175 GSEA both screens had an interferon signature (Table 1 respectively ( Figure 3A and 3B). We were unable to validate an MNoV strain-specific 198 protective effect for any gene ( Figure 3C ). Taken together, these data validate the 199 reproducibility of the CRISPRa screening platform and indicate the potential for false-
200
negatives.
201
We next tested whether overexpression of these genes inhibited production of together, these data demonstrate an isoform specificity for the anti-MNoV mechanism 226 that is conserved across species.
227
Finally, we determined which step of the viral life cycle was targeted by TRIM7.
228
Since ubiquitination can lead to proteaseome-mediated degradation of proteins, we first 229 tested whether the MNoV receptor, CD300lf, was reduced upon TRIM7 overexpression.
230
In HeLa-CD300lf we found no effect of TRIM7 on CD300lf protein levels ( Figure 4A ).
231
We next tested the hypothesis that TRIM7 targets a critical step of MNoV entry.
232
Transfection of MNoV CW3 RNA was unable to rescue MNoV production in human TRIM7
233 isoform 1 expressing BV2 cells indicating that TRIM7 can target a post-entry step of the
234
MNoV life cycle to inhibit viral replication ( Figure 4J ). Tukey's multiple comparison test. ****p<0.0001, ns = not significant. 
